Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 12/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 12/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 12/20 | 1.00 |
| ▸ | PIK3R2 | O00459 | 1/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 8/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660510 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL29394358 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL657898 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL18926572 | 0.93 | PIK3CD (0.86) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL17268366 | 0.93 | PIK3CD (0.86) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL18934404 | 0.92 | PIK3CD (0.84) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| Mandelic Acid SCHEMBL660110 | 0.91 | PIK3CD (0.82) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL16938681 | 0.90 | PIK3CD (0.82) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL459118 | 0.89 | PIK3CD (0.80) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL714987 | 0.89 | PIK3CD (0.80) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | claimed |
| EP-3260453-B1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2021-03-31 | — | — | EP | claimed |
| US-20190070166-A1 | Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease | POSTREL RICHARD (US) | 2019-03-07 | — | — | US | claimed |
| EP-3260453-A1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | Glaxo Group Limited (GB) | 2017-12-27 | — | — | EP | claimed |
| EP-2899191-B1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2017-08-09 | — | — | EP | claimed |
| US-20170015656-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2017-01-19 | — | — | US | claimed |
| US-20160263109-A1 | P13K INHIBITOR FOR TREATMENT OF RESPIRATORY DISEASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-09-15 | — | — | US | claimed |
| EP-2613781-B1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-08-24 | — | — | EP | claimed |
| EP-3057587-A1 | PI3K INHIBITOR FOR TREATMENT OF RESPIRATORY DISEASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2016-08-24 | — | — | EP | claimed |
| EP-3057588-A1 | PI3K INHIBITOR FOR TREATMENT OF RESPIRATORY DISEASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2016-08-24 | — | — | EP | claimed |
| US-8735390-B2 | Polymorphs and salts | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-05-27 | — | — | US | claimed |
| US-8609657-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-12-17 | — | — | US | claimed |
| US-8575162-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-11-05 | — | — | US | claimed |
| US-20130165441-A1 | Novel Polymorphs and Salts | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | claimed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | claimed |
| US-20130131080-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-05-23 | — | — | US | claimed |
| US-20130096117-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-04-18 | — | — | US | claimed |
| US-20130029985-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | claimed |
| US-20120046286-A1 | Novel Compounds | HAMBLIN JULIE NICOLE (GB) | 2012-02-23 | — | — | US | claimed |
| US-20100280029-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165441-A1 | Novel Polymorphs and Salts | PRKDC, PRKACA, MAP3K20 | PIK3CD 153/4885PIK3CA 133/4885PIK3CB 219/4885 |
| US-20130029985-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | PIK3CD 1/4885PIK3CA 2/4885PIK3CB 4/4885 |
| US-20130131080-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | PIK3CD 1/4885PIK3CA 2/4885PIK3CB 4/4885 |
| US-20170015656-A1 | NOVEL COMPOUNDS | IPO5, IPO4, MAP4 | PIK3CD 2049/4885PIK3CA 2869/4885PIK3CB 1717/4885 |
| US-20100280029-A1 | NOVEL COMPOUNDS | PIK3CD, PIK3CA, PIK3C2B | PIK3CD 1/4885PIK3CA 2/4885PIK3CB 4/4885 |
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | PIK3CD 2938/4885PIK3CA 2691/4885PIK3CB 1706/4885 |
| US-20120046286-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | PIK3CD 1/4885PIK3CA 2/4885PIK3CB 4/4885 |
| US-20130096117-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | PIK3CD 1/4885PIK3CA 2/4885PIK3CB 4/4885 |
| US-20160263109-A1 | P13K INHIBITOR FOR TREATMENT OF RESPIRATORY DISEASE | PIK3CA, PIK3CD, PIK3R4 | PIK3CD 2/4885PIK3CA 1/4885PIK3CB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.